Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

601
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
601
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

828
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
828
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

164
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
164
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

614
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
614
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

198
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
198

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lifelong Hypoxia Produces Multigenerational Developmental Lung Disease and Pulmonary Hypertension in Mice.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

A Glycolytic Gatekeeper in Developmental Cardiomyopathy.

JACC. Basic to translational science·2026
Same author

Evaluation of Pulmonary Artery Flow Reserve in Patients With Chronic Thromboembolic Pulmonary Hypertension: A Pilot Study.

Journal of the American Heart Association·2026
Same author

Transcriptome Reprogramming in Heart Failure: The Hidden Splicing Code.

Current cardiology reports·2026
Same author

Barriers and Facilitators of Exercise Participation Among Community-Dwelling Older Adults with Chronic Conditions: A Qualitative Study Using the COM-B Model and Theoretical Domains Framework.

Healthcare (Basel, Switzerland)·2026
Same author

Microencapsulation of cholic acid via complex coacervation enhances sustained release and antibacterial activity against <i>Escherichia coli</i>.

Frontiers in veterinary science·2026

Related Experiment Video

Updated: Dec 28, 2025

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.8K

Targeting Age-Related Pathways in Heart Failure.

Haobo Li1, Margaret H Hastings1, James Rhee1,2

  • 1From the Corrigan Minehan Heart Center, Massachusetts General Hospital, Harvard Medical School, Boston (H.L., M.H.H., J.R., L.E.T., J.D.R., A.R.).

Circulation Research
|February 21, 2020
PubMed
Summary

Cardiac aging leads to heart failure, but exercise reveals new pathways to combat this decline. Research highlights exercise as a platform for discovering novel therapeutic targets for age-related heart disease.

Keywords:
agingepigeneticsexerciseheart failuresenescence

More Related Videos

Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart
11:53

Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart

Published on: June 14, 2020

8.0K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.2K

Related Experiment Videos

Last Updated: Dec 28, 2025

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.8K
Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart
11:53

Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart

Published on: June 14, 2020

8.0K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.2K

Area of Science:

  • Cardiology
  • Gerontology
  • Molecular Biology

Background:

  • Aging causes cardiac structural and functional decline, increasing heart failure risk.
  • The growing elderly population heightens the urgency for interventions against age-related cardiac issues.
  • Current understanding of cardiac aging and general aging processes remains limited.

Purpose of the Study:

  • To review recent findings on molecular mechanisms underlying age-related heart failure.
  • To highlight exercise as a key experimental model for identifying therapeutic targets.
  • To address the need for novel interventions in chronic cardiovascular disease.

Main Methods:

  • Literature review of recent studies on cardiac aging.
  • Analysis of molecular pathways involved in age-related cardiac decline.
  • Examination of exercise interventions and their effects on cardiac health.

Main Results:

  • Novel pathological and cardioprotective pathways associated with aging have been identified.
  • Exercise has emerged as a significant factor in understanding and potentially preventing cardiac aging.
  • Specific molecular mechanisms driving age-related heart failure are being elucidated.

Conclusions:

  • Understanding the molecular basis of cardiac aging is crucial for developing effective treatments.
  • Exercise provides a valuable platform for discovering new therapeutic targets for age-related heart failure.
  • Further research into exercise-mediated cardioprotection can lead to novel interventions for chronic heart disease.